Evidence Hub

A Randomized, Double-Blind, Placebo-Controlled Crossover Study to Evaluate the Pharmacodynamic Effects of Suzetrigine in Healthy Male Adults

ClinicalTrials.gov · COMPLETED, 2025

20 participants

Abstract

This is a randomized, double-blind, placebo-controlled within-participant crossover study in healthy male participants 18-55 years of age to assess pain tolerance during a cold pressor test.

The study will be conducted at a single center in New Zealand.

Conditions: Pain Detection, Pain Threshold.

Primary outcome: Change from baseline pain score after dosing with suzetrigine vs. placebo; Time to reach Pain Detection Threshold (PDT) and Pain Tolerance Threshold (PTT) after dosing with suzetrigine vs placebo.

Enrollment: 20 participants.

How strong is the evidence?

Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 20 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free